BCAM
BIIB icon

Boston Common Asset Management’s Biogen BIIB Stock Holding History

Boston Common Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,456
Closed -$7.99M – 313
2024
Q2 		$7.99M Sell
34,456
-10,810
-24% -$2.35M 0.2% 148
2024
Q1 		$9.76M Sell
45,266
-13,445
-23% -$3.15M 0.23% 134
2023
Q4 		$15.2M Sell
58,711
-6,047
-9% -$1.49M 0.35% 107
2023
Q3 		$16.6M Buy
64,758
+24,868
+62% +$6.65M 0.4% 95
2023
Q2 		$11.4M Sell
39,890
-116
-0.3% -$34.5K 0.24% 136
2023
Q1 		$11.1M Buy
40,006
+2,774
+7% +$768K 0.23% 144
2022
Q4 		$10.3M Buy
37,232
+11
+0% +$3.11K 0.49% 74
2022
Q3 		$9.94M Sell
37,221
-35,692
-49% -$7.58M 0.52% 70
2022
Q2 		$14.9M Sell
72,913
-1,882
-3% -$385K 0.74% 46
2022
Q1 		$15.8M Sell
74,795
-32,976
-31% -$7.17M 0.68% 51
2021
Q4 		$25.9M Buy
107,771
+7,511
+7% +$1.93M 1.04% 31
2021
Q3 		$28.4M Sell
100,260
-27
-0% -$8.85K 1.23% 25
2021
Q2 		$34.7M Buy
100,287
+60,503
+152% +$18.3M 1.49% 15
2021
Q1 		$11.1M Sell
39,784
-5,070
-11% -$1.37M 0.7% 50
2020
Q4 		$11M Buy
44,854
+9,191
+26% +$2.37M 0.77% 45
2020
Q3 		$10.1M Sell
35,663
-4,827
-12% -$1.35M 0.96% 29
2020
Q2 		$10.8M Buy
40,490
+2,735
+7% +$822K 1.16% 22
2020
Q1 		$11.9M Buy
37,755
+260
+0.7% +$78.9K 1.68% 13
2019
Q4 		$11.1M Sell
37,495
-1,023
-3% -$284K 1.3% 19
2019
Q3 		$8.97M Buy
38,518
+7,745
+25% +$1.8M 1.11% 25
2019
Q2 		$7.2M Buy
30,773
+256
+0.8% +$59.1K 0.9% 36
2019
Q1 		$7.21M Buy
30,517
+5,942
+24% +$1.87M 0.94% 31
2018
Q4 		$7.39M Buy
24,575
+2,052
+9% +$655K 1.08% 25
2018
Q3 		$7.96M Sell
22,523
-1,644
-7% -$566K 0.99% 25
2018
Q2 		$7.01M Sell
24,167
-1,379
-5% -$388K 0.87% 45
2018
Q1 		$7M Sell
25,546
-4,499
-15% -$1.4M 0.82% 45
2017
Q4 		$9.57M Buy
30,045
+1,389
+5% +$446K 1.14% 21
2017
Q3 		$8.97M Buy
28,656
+1,463
+5% +$433K 1.12% 19
2017
Q2 		$7.38M Buy
27,193
+3,707
+16% +$980K 0.97% 28
2017
Q1 		$6.42M Buy
23,486
+61
+0.3% +$17.2K 0.87% 33
2016
Q4 		$6.64M Buy
23,425
+147
+0.6% +$43.6K 0.97% 34
2016
Q3 		$7.29M Sell
23,278
-4,491
-16% -$1.33M 0.4% 83
2016
Q2 		$6.71M Buy
27,769
+3,094
+13% +$815K 0.39% 90
2016
Q1 		$6.42M Buy
24,675
+2,720
+12% +$718K 0.36% 94
2015
Q4 		$6.73M Buy
21,955
+3,272
+18% +$940K 0.38% 91
2015
Q3 		$5.45M Buy
18,683
+1,385
+8% +$457K 0.33% 103
2015
Q2 		$6.99M Sell
17,298
-260
-1% -$104K 0.37% 92
2015
Q1 		$7.41M Buy
17,558
+309
+2% +$122K 0.4% 92
2014
Q4 		$5.86M Buy
17,249
+89
+0.5% +$28.8K 0.33% 106
2014
Q3 		$5.68M Buy
17,160
+3,565
+26% +$1.18M 0.32% 112
2014
Q2 		$4.29M Buy
13,595
+114
+0.8% +$34.3K 0.23% 131
2014
Q1 		$4.12M Buy
13,481
+29
+0.2% +$9.21K 0.23% 132
2013
Q4 		$3.76M Sell
13,452
-2,753
-17% -$712K 0.21% 140
2013
Q3 		$3.9M Buy
16,205
+166
+1% +$37.2K 0.23% 139
2013
Q2 		$3.45M Buy
+16,039
New +$3.43M 0.21% 147

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boston Common Asset Management's BIIB Position: Q3 2024 in Review

Boston Common Asset Management sold out of Biogen (BIIB) in Q3 2024, closing a stake of 34,456 shares — an estimated $7.99M sold.

Boston Common Asset Management first reported a position in BIIB in Q2 2013 and held it in 45 quarters. The position peaked at $34.7M in Q2 2021. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • Boston Common Asset Management reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
  • Boston Common Asset Management sold 34,456 Biogen shares in Q3 2024, an estimated $7.99M.
  • Boston Common Asset Management first reported a position in Biogen in Q2 2013 and held it in 45 quarters.
  • Boston Common Asset Management's Biogen position peaked at $34.7M in Q2 2021.
  • 916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Boston Common Asset Management's 13F filing for Q3 2024, filed 9 Oct 2024.